Is Helius Medical Stock a Good Investment?
Helius Medical Investment Advice | HSDT |
- Examine Helius Medical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Helius Medical's leadership team and their track record. Good management can help Helius Medical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Helius Medical's business and its evolving consumer preferences.
- Compare Helius Medical's performance and market position to its competitors. Analyze how Helius Medical is positioned in terms of product offerings, innovation, and market share.
- Check if Helius Medical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Helius Medical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Helius Medical Technologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Helius Medical Technologies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Helius Medical Stock
Researching Helius Medical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Helius Medical Techn recorded a loss per share of 4.27. The entity last dividend was issued on the 4th of January 2021. The firm had 1:50 split on the 17th of August 2023.
To determine if Helius Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Helius Medical's research are outlined below:
| Helius Medical Techn generated a negative expected return over the last 90 days | |
| Helius Medical Techn has high historical volatility and very poor performance | |
| Helius Medical Techn has some characteristics of a very speculative penny stock | |
| Helius Medical Techn has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 644 K. Net Loss for the year was (8.85 M) with profit before overhead, payroll, taxes, and interest of 324 K. | |
| Helius Medical Technologies currently holds about 3.27 M in cash with (10.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Helius Medical Techn has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Helius Medical Explores Strategic Alternatives - Marketscreener.com |
Helius Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Helius Medical Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Helius Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Helius Medical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Helius Medical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-11 | 2023-03-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2018-03-12 | 2017-12-31 | -0.15 | -0.1848 | -0.0348 | 23 | ||
2023-03-09 | 2022-12-31 | -0.13 | -0.17 | -0.04 | 30 | ||
2024-08-12 | 2024-06-30 | -0.5 | -0.64 | -0.14 | 28 | ||
2022-08-15 | 2022-06-30 | -1.12 | -0.97 | 0.15 | 13 | ||
2022-03-14 | 2021-12-31 | -1.16 | -1.31 | -0.15 | 12 | ||
2022-11-14 | 2022-09-30 | -0.21 | -0.03 | 0.18 | 85 | ||
2017-08-11 | 2017-06-30 | -0.05 | -0.3 | -0.25 | 500 |
Know Helius Medical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Helius Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Helius Medical Technologies backward and forwards among themselves. Helius Medical's institutional investor refers to the entity that pools money to purchase Helius Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | St Germain D J Co Inc | 2024-09-30 | 2.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 17.8 K | Susquehanna International Group, Llp | 2024-06-30 | 16.3 K | Vanguard Group Inc | 2024-09-30 | 12.6 K | Tower Research Capital Llc | 2024-06-30 | 6.9 K | Ubs Group Ag | 2024-06-30 | 1.5 K | Corecap Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 80.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 37.0 |
Helius Medical's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.7 M.Market Cap |
|
Helius Medical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.15) | (1.21) | |
| Return On Capital Employed | (2.14) | (2.24) | |
| Return On Assets | (1.15) | (1.21) | |
| Return On Equity | (3.77) | (3.95) |
Determining Helius Medical's profitability involves analyzing its financial statements and using various financial metrics to determine if Helius Medical is a good buy. For example, gross profit margin measures Helius Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Helius Medical's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Helius Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Helius Medical Technologies. Check Helius Medical's Beneish M Score to see the likelihood of Helius Medical's management manipulating its earnings.
Evaluate Helius Medical's management efficiency
Helius Medical Techn has return on total asset (ROA) of (0.7606) % which means that it has lost $0.7606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6197) %, meaning that it created substantial loss on money invested by shareholders. Helius Medical's management efficiency ratios could be used to measure how well Helius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to drop to -2.24 in 2024. At this time, Helius Medical's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 384.8 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 1.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.87 | 3.67 | |
| Tangible Book Value Per Share | 3.83 | 3.64 | |
| Enterprise Value Over EBITDA | 0.02 | 0.02 | |
| Price Book Value Ratio | 2.08 | 2.18 | |
| Enterprise Value Multiple | 0.02 | 0.02 | |
| Price Fair Value | 2.08 | 2.18 | |
| Enterprise Value | -237.6 K | -225.7 K |
Management at Helius Medical Techn focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 1.614 |
Basic technical analysis of Helius Stock
As of the 28th of November, Helius Medical retains the Market Risk Adjusted Performance of (0.11), standard deviation of 9.08, and Risk Adjusted Performance of (0.02). Helius Medical technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Helius Medical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Helius Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Helius Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Helius Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buckman Paul over three months ago Acquisition by Buckman Paul of 31000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Favit-van Pelt Antonella R. over three months ago Acquisition by Favit-van Pelt Antonella R. of 277000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Dane Andreeff over three months ago Acquisition by Dane Andreeff of 808000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Perkins Sherrie L over a year ago Acquisition by Perkins Sherrie L of 83054 shares of Helius Medical subject to Rule 16b-3 | ||
Mathiesen Jeffrey S over a year ago Acquisition by Mathiesen Jeffrey S of 2693000 shares of Helius Medical subject to Rule 16b-3 |
Helius Medical's Outstanding Corporate Bonds
Helius Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Helius Medical Techn uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Helius bonds can be classified according to their maturity, which is the date when Helius Medical Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Helius Medical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Helius Medical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 5.65 | |||
| Coefficient Of Variation | (2,465) | |||
| Standard Deviation | 9.08 | |||
| Variance | 82.49 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.75) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 60.51 | |||
| Value At Risk | (11.46) | |||
| Potential Upside | 13.16 | |||
| Skewness | 2.33 | |||
| Kurtosis | 12.65 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 5.65 | |||
| Coefficient Of Variation | (2,465) | |||
| Standard Deviation | 9.08 | |||
| Variance | 82.49 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.75) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 60.51 | |||
| Value At Risk | (11.46) | |||
| Potential Upside | 13.16 | |||
| Skewness | 2.33 | |||
| Kurtosis | 12.65 |
Consider Helius Medical's intraday indicators
Helius Medical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Helius Medical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Helius Medical time-series forecasting models is one of many Helius Medical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Helius Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Helius Stock media impact
Far too much social signal, news, headlines, and media speculation about Helius Medical that are available to investors today. That information is available publicly through Helius media outlets and privately through word of mouth or via Helius internal channels. However, regardless of the origin, that massive amount of Helius data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Helius Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Helius Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Helius Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Helius Medical alpha.
Helius Medical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Helius Medical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Helius Medical Corporate Management
| Brian Bapty | VP of Strategy and Bus. Devel. | Profile | |
| CPA CPA | Treasurer, CFO | Profile | |
| Lawrence Picciano | Quality Engineering | Profile | |
| Antonella MD | Chief Officer | Profile |
Additional Tools for Helius Stock Analysis
When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.